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Objectives: Immune cell migration from the bloodstream to target tissues is a hallmark 
of rheumatoid arthritis (RA) pathogenesis. The role of chemoattractants, mainly chemo-
kines, and their possible targeting for therapeutic purposes have been under intense 
investigation over the last few years but the results were not as satisfactory as expected. 
The insulin-like growth factor binding protein 6 (IGFBP6), a direct inhibitor of insulin-like 
growth factor (IGF)-II, also exerts IGF-independent effects including tumor cell migration 
in vitro. We aimed to assess the expression of this protein in serum, synovial fluid, and 
synovial tissue (ST) of RA patients and to identify its possible chemotactic role in this 
disorder.
Methods: IGFBP6 was measured in RA patients and healthy donors (HD) sera 
by Luminex xMAP® technology and in ST of RA patients and osteoarthritis (OA) controls 
by immunofluorescence. The identification of circulating IGFBP6+ cells was evaluated by 
flow cytometry and an in vitro migration assay was arranged.
results: We demonstrated that IGFBP6 is able to induce greater in vitro migration of RA 
as compared to HD and OA T lymphocytes and is overexpressed in serum and ST of RA 
patients. This in vitro chemotactic activity can be partially inhibited by dexamethasone.
conclusion: Our findings suggest a pathogenic role of IGFBP6 in RA and support its 
possible targeting for therapeutic purposes.
Keywords: rheumatoid arthritis, igFBP6, cell migration, synovial membrane
inTrODUcTiOn
Rheumatoid arthritis (RA) is a chronic inflammatory disorder that predominantly affects the joints. 
Immune cell recruitment from the bloodstream to the sites of inflammation is a crucial event 
in the development of synovitis. An excessive migration of these cells and their retention in the 
synovial environment, together with impaired apoptotic processes, chronically maintain the inflam-
matory response with the development of hyperplastic synovium and neoangiogenic phenomena. 
Rheumatoid synovial pannus can lead to damage of articular cartilage and bone with progressive joint 
destruction (1). Although chemokines and chemokine receptors, overexpressed in RA serum and 
synovial tissue (ST), appear to be leading players in orchestrating leukocyte recruitment to inflamed 
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synovial membrane (2), the selective targeting of chemokines and 
their receptors has not yet led to the expected results in clinical 
trials (3, 4).
Cartilage and bone damage in RA may be considered the final 
result of catabolic mechanisms in the joint space exceeding ana-
bolic pathways, similar to what occurs in tumor development and 
invasion. The predominating catabolic processes are thought to be 
cytokine-driven, upregulating proteases responsible for collagen 
and proteoglycan degradation. Since insulin-like growth factors 
(IGFs) are thought to be involved in the maintenance of articular 
cartilage and bone homeostasis, also in part through their ability 
to reverse the catabolic effects mediated by pro-inflammatory 
cytokines, a number of studies tried to analyze their role in 
rheumatoid synovitis. The results, however, were not conclusive.
In this setting, the regulation of IGF actions is critically 
important because of their essential physiological roles and the 
potential contribution of their dysregulation to a number of 
common diseases processes, including cancer and atherosclero-
sis. In fact, IGF activities are regulated by a family of six specific 
high-affinity binding proteins (IGFBPs) that are all able to 
inhibit IGF actions. Among the six IGFBPs, insulin-like growth 
factor binding protein 6 (IGFBP6) sparked increasing interest in 
recent years for its relative specificity in inhibiting IGF-II, whose 
circulating levels are several-fold higher than those of IGF-I in 
adult humans, thereby confirming its relevant physiological 
role, and for its ability to exert a number of IGF-independent 
activities. In particular, IGFBP6 appears to be able to enter the 
nucleus where it modulates cell differentiation and survival (5), 
to interfere with angiogenetic processes and, intriguingly, to 
promote cell migration. In particular, recent data suggest that 
it can induce tumor cell migration thereby worsening disease 
prognosis (6–9). On this basis, the investigation of IGFBP6 in RA 
may be of great interest in order to unmask a possible pathogenic 
role of this molecule in driving immune cell migration to target 
inflamed tissues.
Very recently, circulating antibodies reactive against citrulli-
nated IGFBP6 have been described in RA patients (10). However, 
to the best of our knowledge, no data are available about serum 
concentration of IGFBP6 and its functional effects in RA. 
Moreover, only an outdated study unsuccessfully attempted to 
measure IGFBP6 in RA synovial fluid (SF), but it is to note that 
the assay employed to detect IGFBP6 in this investigation was 
scarcely sensitive (11). Therefore, the purpose of our study was 
to assess the expression of this protein with a highly sensitive 
assay in serum, SF, and ST of RA patients as well as to identify its 
possible chemotactic role in this disorder.
MaTerials anD MeThODs
study cohort
Seventy patients with RA according to the 1987 American 
College of Rheumatology classification criteria were enrolled 
(12). Twenty-five sex- and age-matched healthy donors (HD) and 
18 patients with osteoarthritis (OA) acted as normal and disease 
controls, respectively. RA patients were receiving stable biologic 
and/or conventional synthetic diseases modifying anti-rheumatic 
drugs (bDMARDs and csDMARDs respectively) over the 
6  months prior to enrollment. The whole study was approved 
by the local ethic committee, and written informed consent was 
obtained in accordance with the Declaration of Helsinki.
igFBP6 assessment in serum and sF
Insulin-like growth factor binding protein 6 concentration was 
assessed in 34 RA and 12 HD serum samples and in 15 RA and 12 
OA SF samples. Briefly, secreted IGFBP6 was measured using the 
MILLIPLEX MAP® kit based on the Luminex xMAP® technology 
(EMD Millipore Corp., St. Charles, MO, USA) according to the 
manufacturer’s protocol. The samples were incubated with the 
antibody-coupled microsphere, and later on with biotinylated 
detection antibody, then streptavidin–phycoerythrin (Pe) was 
added. The complexes were then scanned with a FLEXMAP3D 
reader (Luminex, Austin, TX, USA) set with 50 µl and 50 beads per 
bead set. All readings were performed by Bioclarma (Bioclarma 
srl, Torino, Italy).
igFBP6 assessment in Peripheral Blood 
Mononuclear cells (PBMcs)
Heparinized blood samples were obtained by five RA patients 
and five HD. PBMCs were isolated by density gradient, and 
surface staining was performed with fluorescein isothiocyanate, 
Pe or Pe-Cy7-labeled anti-human CD3, CD4, CD8, CD16, 
CD56, CD20, CD45RA, and CD45RO monoclonal antibod-
ies and respective isotypes. After surface staining, cells were 
fixed with 4% paraformaldehyde and permeabilized with 0.1% 
saponin blocking buffer for subsequent intracellular staining 
with unconjugated rabbit anti-human IGFBP6 primary Ab and 
AlexaFluor647 donkey anti-rabbit secondary Ab. Up to four dif-
ferent fluorochromes were used in the same vial, and samples were 
analyzed using FACScalibur flow cytometer and CellQuestPro™ 
software (BD, San Jose, CA, USA).
synovial specimens and 
immunofluorescence staining
Synovial biopsies were collected from seven patients with 
RA and six age- and gender-matched patients with OA who 
underwent surgical knee joint replacement. For routine his-
topathological analysis, paraffin-embedded synovial sections 
were deparaffinized and stained with hematoxylin and eosin. 
For immunofluorescence staining, tissue sections (5 µm thick) 
were boiled for 10  min in sodium citrate buffer (10  mM, pH 
6.0), washed in phosphate-buffered saline (PBS), incubated in 
2 mg/ml glycine for 10 min to quench autofluorescence caused 
by free aldehydes, and subsequently blocked for 1  h at room 
temperature with 1% bovine serum albumin (BSA) in PBS. 
The sections were then incubated overnight at 4°C with the 
following primary Abs diluted in PBS with 1% BSA: rabbit 
monoclonal anti-human CD3 (1:100 dilution; catalog number 
ab109531; Abcam, Cambridge, UK), mouse monoclonal Abs 
against human CD20 (1:200 dilution; catalog number M0755; 
Dako, Glostrup, Denmark), CD3 (1:10 dilution; catalog number 
ab17143; Abcam), CD14 (1:50 dilution; catalog number 347490; 
BD PharMingen, Heidelberg, Germany), CD31 (1:25 dilution; 
TaBle 1 | Demographic, clinical, and serological features of ra patient 
cohort.
Number of RA patients 70
Female gender 56 (80)
Age (years)a 57 ± 2.2
Age at diagnosis (years)a 48 ± 0.9
Disease duration (years)a 10 ± 2
Autoantibodies
None 20 (29)
RF+/− anti-CCP+ 50 (71)
Erosions 41 (58)
Nodules 4 (6)
Pulmonary involvement 6 (8)
csDMARDs 70 (100)
bDMARDs 38 (54)
DAS-28a 2.9 ± 1.2
aValues are expressed as mean ± SEM. All other values are expressed as number of 
patients (%).
csDMARDs, conventional synthetic diseases modifying anti-rheumatic drugs; 
bDMARDs, biologic diseases modifying anti-rheumatic drugs; DAS, disease activity 
score; RA, rheumatoid arthritis.
FigUre 1 | insulin-like growth factor binding protein 6 (igFBP6) expression in serum (a) of rheumatoid arthritis (ra) patients and healthy donors 
(hD) and in synovial fluid (sF) of ra patients and osteoarthritis (Oa) controls (c). IGFBP6 concentration is significantly higher in RA serum compared to HD 
and is significantly lower in RA SF compared to OA SF. Correlation between serum IGFBP6 and patients’ age (B), SF IGFBP6 and SF white blood cell (WBC) count 
(D), and SF platelet (PLT) count (e). SF IGFBP6 concentration is inversely correlated to both SF WBC and PLT counts. p values shown in panels (a,c) were 
calculated with Mann–Whitney U test.
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catalog number ab9498; Abcam), CD68 (1:50 dilution; catalog 
number M0876; Dako), vimentin (VIM) (1:50 dilution; catalog 
number M7020; Dako), and rabbit polyclonal anti-human 
IGFBP6 (1:50 dilution; catalog number ab135606; Abcam). 
The day after, the slides were washed three times in PBS and 
incubated for 45  min at room temperature in the dark with 
Rhodamine Red-X-conjugated goat anti-rabbit IgG or Alexa 
Fluor-488-conjugated goat anti-mouse IgG (Invitrogen, San 
Diego, CA, USA) diluted 1:200 in PBS with 1% BSA, as second-
ary Abs. Double immunofluorescence staining was performed 
by mixing mouse and rabbit primary Abs and subsequently 
mixing fluorochrome-conjugated secondary Abs. Irrelevant 
isotype-matched and concentration-matched mouse and rabbit 
IgG (Sigma-Aldrich, St. Louis, MO, USA) were used as negative 
controls. Nuclei were counterstained with 4′,6-diamidino-
2-phenylindole (DAPI; Chemicon International, Temecula, 
CA, USA). Synovial sections were then mounted with an anti-
fade mounting medium and examined with a Leica DM4000 
B microscope (Leica Microsystems, Mannheim, Germany). 
Fluorescence images were captured with a Leica DFC310 FX 
1.4-megapixel digital color camera equipped with the Leica 
software application suite LAS V3.8 (Leica Microsystems). 
Densitometric analysis of the intensity of immunofluorescent 
staining was performed on digitized images using the free-share 
ImageJ software (NIH, Bethesda, MD, USA; online at http://
rsbweb.nih.gov/ij).
Migration assay
A total of 1  ×  106 PBMCs isolated as above from eight RA 
patients, four OA patients, and six HD were resuspended in 
100  µl of complete medium with or without dexamethasone 
(dex) 5 × 10−6 M and seeded on the upper side of a 3 µm pore 
transwell. Six hundred microliters of either complete medium 
with recombinant IGFBP6 (1  µg/ml) or complete medium 
without the recombinant protein were put in the basolateral 
side of the transwell. After 2 h and 30 min incubation at 37°C, 
5% CO2, the basolateral medium was harvested for counting of 
migrated cells and their phenotypic analysis by flow cytometry 
as detailed above. IGFBP6-induced cell migration was defined as 
the percentage of cells migrated in the medium with the protein 
FigUre 2 | intracellular expression of insulin-like growth factor binding protein 6 (igFBP6) in peripheral blood mononuclear cells (PBMcs) from 
rheumatoid arthritis (ra) patients and healthy donors (hD) (a) and representative flow cytometry dot plots (B,c) gated on total PBMcs of igFBP6 
expression in cD3+ cells and cD16+ cells in a patient with ra. In RA PBMCs CD16+IGFBP6+ cell percentage is higher compared to HD while the percentage 
of CD3+IGFBP6+ cells is lower compared to HD. In addition, in HD the largest proportion of IGFBP6+ T cells coexpresses CD45RA. All p values were calculated with 
Mann–Whitney U test.
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normalized for the control (cell migrated in the medium without 
the protein).
statistical analysis
Data were analyzed with SPSS 21.0 software using the Mann–
Whitney U test and the Spearman’s correlation coefficient. 
p values <0.05 were considered significant.
resUlTs
igFBP6 expression in ra serum and sF
Table  1 summarizes the demographic and clinical features of 
RA patient cohort. We first sought to investigate the concentra-
tion of IGFBP6 in the serum of RA patients and we found that 
it was significantly increased compared to HD (Figure  1A). 
Intriguingly, IGFBP6 serum concentration was directly cor-
related with age in RA patients but not in HD (Figure 1B). In 
striking contrast, the concentration of IGFBP6 in RA SF was 
significantly lower compared to OA SF (Figure 1C). Moreover, 
when cumulating RA and OA patients, we observed an inverse 
relationship between IGFBP6 concentration and the number 
of both white blood cells (WBCs) and platelets (PLTs) in SF 
(Figures 1D,E).
igFBP6 intracellular expression in ra  
and hD Peripheral Blood
Subsequently, we assessed intracellular expression of IGFBP6 
in circulating PBMCs from RA patients and HD. In HD, 
IGFBP6 was mainly expressed by PB CD3+ T  lymphocytes 
FigUre 3 | insulin-like growth factor binding protein 6 (igFBP6) expression in synovial tissue from patients with rheumatoid arthritis (ra) and  
osteoarthritis (Oa). Representative microphotographs of synovial membrane sections from patients with RA (a,c,e) and patients with OA (B,D,F) are shown. 
(a,B) Hematoxylin and eosin (H&E) staining. (c,D) Double immunofluorescence staining for CD3 (red) and CD20 (green) with 4′,6-diamidino-2-phenylindole (DAPI, 
blue) counterstain for nuclei. RA synovial membrane displays either diffuse immune cell infiltrates or ectopic lymphoid structures composed of T and B cells (a,c). 
Few scattered T and B cells are present in OA synovium (B,D). (e,F) Immunofluorescence staining for IGFBP6 (red) with DAPI (blue) counterstain. IGFBP6 is strongly 
expressed in different cells of the lining and sublining layers of RA synovium (e). Faint expression of IGFBP6 is detected in OA synovium (F). Arrowheads indicate 
synovial lining layer. Arrows indicate microvessels in synovial sublining layer. Original magnification: ×10 (a,B), ×20 (c,D), and ×40 (e,F). Scale bar: 200 µm (a,B), 
100 µm (c,D), and 50 µm (e,F). (g) Densitometric analysis of IGFBP6 immunofluorescent staining intensity in lining and sublining layers of RA (n = 7) and OA (n = 6) 
synovium expressed as optical density in arbitrary units (a.u.). Data are mean ± SD. Student’s t-test was used for statistical analysis.
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FigUre 4 | insulin-like growth factor binding protein 6 (igFBP6) expression in different synovial resident cell types. Representative microphotographs of 
synovial sections from rheumatoid arthritis (RA) patients (a,c,e) and osteoarthritis (OA) controls (B,D,F) subjected to double immunofluorescence staining for 
IGFBP6 (red) and the pan-endothelial cell marker CD31 (green) (a,B), the fibroblast marker VIM (green) (c,D), or the macrophage marker CD68 (green) (e,F). Nuclei 
are counterstained with 4′,6-diamidino-2-phenylindole (DAPI; blue). In RA synovium, IGFBP6 is strongly expressed in CD31+ vascular endothelial cells (a), VIM+ 
fibroblast-like synoviocytes (FLS) (c), and CD68+ macrophages (e). Weak IGFBP6 immunopositivity is detectable in the same cell types of OA synovium (B,D,F). 
Insets: higher magnifications of double-immunopositive cells from the respective panels. Note the intense immunopositivity for IGFBP6 localized either in the 
cytoplasm or in the nucleus of RA synovial endothelial cells and FLS. Original magnification: ×40 (a–F). Scale bar: 50 µm (a–F).
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and the evaluation of CD45 isoforms revealed that the vast 
majority of them were naïve T  cells (CD45RA+CD45RO−) 
(Figure 2A). Conversely, in RA patients IGFBP6 was mainly 
detected in PB CD16+ monocytes and only a small proportion 
of CD3+ cells coexpressed IGFBP6 (Figure 2A). IGFBP6 was 
also detected in a small proportion of CD20+ B lymphocytes, 
but no differences could be observed between RA and HD. 
(Figures  2B,C) show two representative stainings for CD3 
and CD16 in RA.
igFBP6 expression in ra and Oa sT
As displayed in Figures 3A–D, either diffuse immune cell infil-
trates or ectopic lymphoid structures composed of CD3+ T cells 
and CD20+ B cells were detected in RA synovium, whereas OA 
synovial specimens exhibited only a few scattered T and B cells. 
IGFBP6 was strongly expressed in different cells of RA synovial 
lining and sublining layers, including macrophages (type A 
synoviocytes), fibroblast-like synoviocytes (FLS, type B synovio-
cytes), microvessels, and infiltrating immune cells (Figure 3E). 
On the contrary, faint expression of IGFBP6 was detected in cells 
of OA synovium (Figure 3F). Indeed, densitometric analysis of 
immunofluorescent staining intensity on ST sections showed 
that IGFBP6 protein expression was significantly increased 
either in the lining or in the sublining layers of RA synovium 
compared with OA (p < 0.001 for both) (Figure 3G). To specifi-
cally investigate the expression of IGFBP6 in different synovial 
resident cell types, we carried out double immunofluorescence 
staining combining anti-IGFBP6 Abs with Abs raised against the 
pan-endothelial cell marker CD31, the fibroblast marker VIM 
and the macrophage marker CD68 (Figures  4A–F). As shown 
in Figures 4A–F, IGFBP6 expression was strongly increased in 
CD31+ vascular endothelial cells, VIM+ FLS, and CD68+ mac-
rophages of RA ST with respect to OA. Of note, strong IGFBP6 
immunopositivity was localized either in the cytoplasm or in the 
FigUre 5 | insulin-like growth factor binding protein 6 (igFBP6) expression in synovial infiltrating immune cells. Representative microphotographs of 
synovial sections from rheumatoid arthritis (RA) patients (a,c) and osteoarthritis (OA) controls (B,D) double immunostained for IGFBP6 (red) and the T-cell marker 
CD3 (green) (a,B) or the monocyte marker CD14 (green) (c,D). Nuclei are counterstained with 4′,6-diamidino-2-phenylindole (DAPI; blue). Numerous CD3+ T cells 
displaying strong immunopositivity for IGFBP6 (yellow cytoplasmic staining) are present in RA synovial membrane (a). Only a few CD14+ monocytes coexpressing 
IGFBP6 can be observed in RA synovium (c). Original magnification: ×40 (a–D). Scale bar: 50 µm (a–D).
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nucleus of RA synovial endothelial cells and FLS as compared 
with very weak signal detected in the same cell types of OA 
synovium (Figures 4A–D, insets). As far as infiltrating immune 
cells are concerned, IGFBP6/CD3 double immunofluorescence 
staining revealed that the majority of CD3+ T cells infiltrating RA 
synovium displayed very strong immunopositivity for IGFBP6 as 
compared with OA controls (Figures 5A,B). On the contrary, a 
few IGFBP6-expressing CD14+ monocytes were observed both in 
RA and OA ST (Figures 5C,D).
igFBP6 induces immune cell Migration 
Which is Partly inhibited by dex
Finally, we aimed at demonstrating whether IGFBP6 may act as 
a chemotactic stimulus for RA immune cells in  vitro. For this 
purpose, we set up a migration assay and observed that IGFBP6 
was able to induce substantial migration of RA, compared to OA 
and HD cells (Figure 6A). We then characterized RA-migrated 
cells by flow cytometry and observed that over 80% of them were 
CD3+ T lymphocytes, while the remaining 20% was a combina-
tion of CD20+ and CD16+ cells (Figure  6B). Furthermore, the 
addition of dex to the upper chamber was able to partially inhibit 
the migration of RA cells (Figure 6C). Although partially inhibit-
ing the migration of RA cells, dex did not affect the proportion 
of migrated cell types being CD3+ cells still the majority of them 
(Figure 6D). Interestingly, the proportion of OA-migrated cells 
was comparable to that of HD, but with different proportions of 
cell types in comparison to HD and RA, being the percentage of 
CD3+ cells significantly lower and the percentage of CD16+ cells 
significantly higher. Of interest, all migrated cells coexpressed 
intracellular IGFBP6.
DiscUssiOn
In recent years, the protein IGFBP6 has been extensively 
investigated in tumor biology. Although it appears to exert an 
inhibitory effect on the tumorigenic properties of IGF-II (5, 6), 
this protein has been raising a growing interest for its proper-
ties in promoting cancer cell migration (6–9). On the basis of 
this observation, we tried to analyze a possible role of IGFBP6 
in a chronic inflammatory disorder such as RA, where pannus 
development and cartilage and bone damage at the joint level 
recall tumor development and invasion. The results of the pre-
sent study demonstrated for the first time that the serum levels 
of this protein are higher in RA than HD. A number of studies 
have investigated circulating IGFBP6 levels in various neoplastic 
and non-malignant disorders, including renal, neurologic and 
ocular diseases, and type 1 diabetes (T1D) in order to evaluate 
its clinical relevance. However, the majority of these studies gave 
conflicting data and did not provide significant results from a 
pathogenic and/or clinical point of view, due to a number of 
methodological limits (13). Of some interest, studies investigat-
ing IGFBP6 in T1D showed higher serum levels of this protein 
in patients with respect to HD and a direct correlation between 
higher IGFBP6 levels and diabetic complications (14–16). To 
note, however, these studies mainly addressed IGF-II-dependent 
effects of IGFBP6 and speculated that the increase of IGFBP6 in 
FigUre 6 | In vitro migration assay. Insulin-like growth factor binding protein 6 (IGFBP6) is able to induce the migration of rheumatoid arthritis (RA) but not 
healthy donors (HD) and osteoarthritis (OA) peripheral blood mononuclear cells (a). The addition of dexamethasone (dex) in the upper chamber of the transwell 
partly inhibited such RA cell migration (B). The majority of RA-migrated cells are CD3+ T lymphocytes (c) and the addition of dex does not affect the proportion of 
migrated cells (D). All p values are calculated with Mann–Whitney U test.
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T1D patients could be the consequence of increased IGF-II levels 
induced by chronic hyperglycemia (16).
It is intriguing to observe that, similar to what observed in 
the present study, serum IGFBP6 increase was more evident in 
older patients in several studies. Increased IGFBP6 levels were 
observed in the serum of aging mice (17) and humans (18) or in 
senescence induced by doxorubicin in colon cancer (19) or by 
hydrogen peroxide in fibroblasts (20). It is well known that RA is 
associated with accelerated senescence of the immune response 
(21), and, therefore, it is intriguing to speculate that chronic 
inflammation and disease evolution of RA may represent the 
stimulus for the progressive increase of IGFBP6 in serum. This 
hypothesis may be strengthened by the observation that neither 
different disease activity nor different treatment, but only age, 
and in consequence disease duration, affected IGFBP6 serum 
concentration in our study.
The IGF-II/IGFBPs system has been scarcely investigated in 
RA (11, 22–24). As mentioned above, no data regarding serum 
IGFBP6 are available in RA. Interestingly, however, IGF-II serum 
levels were found to be lower in RA than in HD (24). Since IGFBP6 
is a direct antagonist of IGF-II, the lower availability of free IGFs 
in RA serum may be explained by increased binding to circulating 
IGFBP6 that, according to our data, is enhanced in RA compared 
to HD. Since the main inflammatory process takes place at the joint 
level, we sought to evaluate IGFBP6 in SF and ST of RA inflamed 
joint. Surprisingly, we found that SF IGFBP6 was detectable in 
RA, but at a lower level compared to OA. On the contrary, this 
protein was highly expressed in RA, but not OA, ST. Considering 
the IGFBP6 ability to promote tumor cell migration (6–9), the 
overexpression of IGFBP6 in ST may suggest its relevance for 
immune cell migration into inflammatory environment. In order 
to verify this hypothesis, we performed a series of in vitro experi-
ments demonstrating that, in fact, IGFBP6 acts as chemoattractant 
for RA immune cells, in particular T lymphocytes. Although the 
low IGFPB6 concentrations in RA SF seem to be apparently in 
contrast with this idea, our results demonstrated an inverse cor-
relation between these concentrations and WBC count in SF. Since 
IGFBP6 is internalized by target cells (6) and most of the migrated 
cells in our in vitro system coexpressed IGFBP6, it is intriguing 
to speculate that the low concentration of IGFBP6 may be due, 
at least in part, to its internalization by WBC. In addition, since 
IGFBP6 is susceptible of proteolysis by matrix metalloproteinase 
2 (MMP-2) (6) and PLTs are major producer of MMP-2 (25), the 
inverse relationship between PLT count and IGFBP6 level may 
also suggest that proteolysis may be another mechanism leading 
to low IGFBP6 concentrations in RA SF.
The observation that the number of circulating IGFBP6+ 
T cells was significantly lower in RA compared to controls, while 
9Alunno et al. IGFBP6 in RA
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numerous IGFBP6-expressing T lymphocytes could be detected 
in RA ST allows us to speculate that T cells coexpressing IGFBP6 
are no longer detectable in RA PB as they are migrated in the 
synovial membrane. This is supported by the already cited find-
ing showing that the majority of migrated RA T cells coexpress 
IGFBP6 in our in vitro assay. On the other hand, the evidence 
that circulating IGFBP6+CD16+ cells were significantly higher in 
RA PB compared to HD allows us to postulate that monocytes 
may represent the main source of IGFBP6 to be released and 
subsequently internalized by T cells.
Besides infiltrating mononuclear cells, other cell types, includ-
ing FLS, express IGFBP6 in RA ST in our study. In this context, 
it is important to underline that a recent study demonstrated that 
IGF-II expression in RA FLS promotes their proliferation, thereby 
contributing to FLS hyperplasia (26). Moreover, experimental 
data showed IGFBP6 ability to inhibit fibroblast proliferation by 
both IGF-dependent and -independent mechanisms (26). The 
apparent paradox, however, that IGFBP6 was overexpressed in the 
ST of inflamed joints by several cell types other than infiltrating 
lymphocytes, may be explained by either IGFBP6 inefficacy 
in blocking IGF-II or by additional effects exerted by the 
protein. In this context and according to our data, IGFBP6 
was also expressed by synovial microvessels similar to other 
molecules that orchestrate the leukocyte-adhesion cascade. 
Since IGFBP6 can exert an inhibitory role on angiogenesis in 
neoplastic disorders (27), we cannot rule out that the expression 
of this protein on microvessels may be due, at least in part, by 
IGFBP6 activity to limit RA neoangiogenesis. However, on the 
basis of the present demonstration that IGFBP6 is chemotactic 
for RA T  lymphocytes in vitro and that the majority of T cells 
infiltrating RA synovium displayed very strong immunopositivity 
for IGFBP6, it is tempting to speculate that the main pathogenic 
roles exerted by IGFBP6 in RA may be that of T-cell chemoat-
tractant from bloodstream to synovial membrane.
In conclusion, our data highlight the potential roles of IGFBP6 
in RA immune cells in vitro. Among these effects, this protein 
appears to put forward as a novel chemotactic agent driving 
T-cell migration from PB to the inflamed joints in RA and, in 
consequence, as new potential therapeutic target in this disorder. 
This finding may be of great value, since the interference with 
immune cell migration for therapeutic purposes in RA has been 
extensively pursued, but the blockade of chemokines has not 
provided consistent benefit up to now (3, 4). In this context, it 
is of interest our results showing that corticosteroids are able, at 
least in part, to prevent IGFBP6-induced chemotaxis, probably 
through a non-genomic effect considered the celerity of action in 
our in vitro assays (28). Further studies are in progress, therefore, 
to better clarify both pathogenic and therapeutic implications of 
these findings.
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